OIRA Conclusion of EO 12866 Regulatory Review

RIN: 0910-AI31         View EO 12866 Meetings	Received Date: 08/29/2023
Title: Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act
Agency/Subagency: HHS / FDA	Stage: Proposed Rule
Concluded Action: Consistent with Change	Concluded Date: 03/11/2024
Legal Deadline: None	Economically Significant: No
Publication Date:	Unfunded Mandates: No
Major: No	Related To Homeland Security: No
Regulatory Flexibility Analysis Required: No	Small Entities Affected: Businesses
Federalism Implications: No	Affordable Care Act [Pub. L. 111-148 & 111-152]: No
International Impacts: No	Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]: No
Pandemic Response: No